keyword
MENU ▼
Read by QxMD icon Read
search

atazanavir

keyword
https://www.readbyqxmd.com/read/29781044/sleeve-gastrectomy-in-morbidly-obese-hiv-patients-focus-on-anti-retroviral-treatment-absorption-after-surgery
#1
Chloé Amouyal, Marion Buyse, Lea Lucas-Martini, Déborah Hirt, Laurent Genser, Adriana Torcivia, Jean-Luc Bouillot, Jean-Michel Oppert, Judith Aron-Wisnewsky
CONTEXT: Anti-retroviral therapy (ART) dramatically reduced AIDS development, thus enabling patients to live as long as the general population. New challenges have emerged particularly cardiometabolic diseases and weight gain, with some HIV patients seeking bariatric surgery (BS). However, BS outcomes during HIV remain poorly described, with scarce data on ART pharmacokinetic post-BS. OBJECTIVE: Describing sleeve gastrectomy (SG) results in HIV patients in terms of ART pharmacokinetic, HIV control, weight loss, and metabolic outcomes...
May 20, 2018: Obesity Surgery
https://www.readbyqxmd.com/read/29760129/pharmacokinetic-changes-during-pregnancy-according-to-genetic-variants-a-prospective-study-in-hiv-infected-patients-receiving-atazanavir-ritonavir
#2
Emanuele Focà, Andrea Calcagno, Andrea Bonito, Jessica Cusato, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Filippo Castelnuovo, Giovanni Di Perri, Francesco Castelli, Stefano Bonora
Atazanavir/ritonavir concentrations change over pregnancy in HIV-positive patients; the impact of genetic variants is unknown. 20 patients were enrolled: antiretrovirals' plasma and intracellular concentrations were measured in addition to single nucleotide polymorphisms in transport affecting genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1 and pregnane-X-receptor encoding genes affected third trimester atazanavir exposure. In this prospective study genetic variants partially explained the observed inter-patient variability in third-trimester antiretrovirals' exposure...
May 14, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29747123/hiv-aspartyl-protease-inhibitors-modify-the-percentage-of-activated-leukocytes-as-well-as-serum-levels-of-il-17a-and-no-during-experimental-leishmaniasis
#3
Daniele Luísa Ribeiro Alvarenga, Amanda Helen Dos Santos Silva, Jacqueline Araújo Fiuza, Soraya Torres Gaze, Jaquelline Germano de Oliveira, Rodrigo Corrêa Oliveira, Carlos Eduardo Calzavara-Silva, Marcelo Antônio Pascoal-Xavier, Érica Alessandra Rocha Alves
HIV aspartyl protease inhibitors are able to modulate multiple defense mechanisms. However, their influence on the immune response against Leishmania has rarely been investigated. The aim of our study was to investigate whether in vivo treatment with HIV aspartyl protease inhibitors is able to modulate the immune response during Leishmania infection. Using Leishmania (L.) amazonensis-infected mice, we analyzed the disease evolution and parasite load, immunophenotypic profiles of splenic T and B lymphocytes, numbers of lymphoid aggregates in the spleen, percentages of circulating atypical lymphocytes and reactive monocytes, and serum levels of cytokines and nitric oxide (NO) after 30 days of oral treatment with lopinavir/ritonavir (LPV/RTV) or atazanavir (ATV)...
May 7, 2018: International Immunopharmacology
https://www.readbyqxmd.com/read/29745457/subclinical-cardiovascular-disease-in-patients-starting-contemporary-protease-inhibitors
#4
A González-Cordón, M Doménech, M Camafort, M Martínez-Rebollar, B Torres, M Laguno, J Rojas, M Loncà, J L Blanco, J Mallolas, J M Gatell, E de Lazzari, E Martínez
OBJECTIVES: The aim of the study was to assess changes in and factors associated with anatomical [carotid artery intima-media thickness (CIMT)] and functional (arterial stiffness) markers of subclinical cardiovascular disease progression in antiretroviral-naïve patients starting triple combination antiretroviral therapy containing contemporary protease inhibitors. METHODS: This was a planned substudy of the ATADAR (Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients) clinical trial (ClinicalTrials...
May 10, 2018: HIV Medicine
https://www.readbyqxmd.com/read/29731407/cardiovascular-disease-and-use-of-contemporary-protease-inhibitors-the-d-a-d-international-prospective-multicohort-study
#5
Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft
BACKGROUND: Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV. METHODS: The prospective Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study consists of people living with HIV-1 from 11 cohorts in Australia, Europe, and the USA...
May 3, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29718781/long-term-treatment-with-atazanavir-atv-in-real-life-in-belgium-a-retrospective-observational-cohort-of-2264-hiv-patients
#6
Stéphane De Wit, Eric Florence, Linos Vandekerkhove, Jean-Christophe Goffard, Bernard Vandercam, Eric Van Wijngaerden, Michel Moutschen, Rémy Demeester, Patrick Lacor, Marc Delforge, Maartje van Frankenhuijsen, Paul Lacante
Objectives This 5-year follow-up study aimed to assess clinical outcomes of HIV-1 infected adults treated with atazanavir (ATV) in clinical practice in Belgium, to describe patient profiles and characteristics, as well as treatment safety. Methods A multicenter, non-interventional, non-comparative, retrospective cohort study was performed in HIV-1 positive adult patients treated with ATV between 2006 and 2012. Data were collected from 8 AIDS reference centers' databases. All analyses were on-treatment. Sub-analyses were carried out in unboosted ATV treated patients and in females...
May 2, 2018: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29718247/emerging-resistance-mutations-in-pi-naive-patients-failing-an-atazanavir-based-regimen-anrs-multicentre-observational-study
#7
S Lambert-Niclot, M Grude, M L Chaix, C Charpentier, S Reigadas, H Le Guillou-Guillemette, A Rodallec, C Amiel, A Maillard, J Dufayard, T Mourez, A Mirand, J Guinard, B Montes, S Vallet, A G Marcelin, D Descamps, P Flandre, C Delaugerre, L Morand-Joubert
Background: Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. Methods: We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of atazanavir and at failure [two consecutive viral loads (VLs) >50 copies/mL]...
April 27, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29706057/monomorphic-ventricular-tachycardia-due-to-protease-inhibitor-intoxication-by-atazanavir
#8
Byunghyun Kim, Kyung Su Kim
Atazanavir is a protease inhibitor approved for use in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus infection. Atazanavir and other protease inhibitors can sometimes induce corrected QT prolongation and ventricular arrhythmia. A 40-year-old man with no comorbidities, except human immunodeficiency virus 1 infection, presented with palpitations 3 days after an overdose of 150 caps of atazanavir, with suicidal intent. His initial electrocardiogram showed monomorphic ventricular tachycardia, and hyperbilirubinemia was observed in his initial blood test...
April 30, 2018: Clinical and Experimental Emergency Medicine
https://www.readbyqxmd.com/read/29694825/birth-outcomes-for-pregnant-women-with-hiv-using-tenofovir-emtricitabine
#9
COMPARATIVE STUDY
Kathryn Rough, George R Seage, Paige L Williams, Sonia Hernandez-Diaz, Yanling Huo, Ellen G Chadwick, Judith S Currier, Risa M Hoffman, Emily Barr, David E Shapiro, Kunjal Patel
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) had infants at greater risk for very premature birth and death within 14 days after delivery than those assigned to receive zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r). METHODS: Using data from two U...
April 26, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29693401/coupling-of-an-acyl-migration-prodrug-strategy-with-bio-activation-to-improve-oral-delivery-of-the-hiv-1-protease-inhibitor-atazanavir
#10
Murugaiah A M Subbaiah, Nicholas A Meanwell, John F Kadow, Lakshumanan Subramani, Mathiazhagan Annadurai, Thangeswaran Ramar, Salil D Desai, Sarmistha Sinha, Murali Subramanian, Sandhya Mandlekar, Srikanth Sridhar, Shweta Padmanabhan, Priyadeep Bhutani, Rambabu Arla, Susan M Jenkins, Mark R Krystal, Chunfu X Wang, Ramakanth Sarabu
HIV-1 protease inhibitors (PIs), which include atazanavir (ATV, 1), remain important medicines to treat HIV-1 infection. However, they are characterized by poor oral bioavailability and a need for boosting with a pharmacokinetic enhancer, which results in additional drug-drug interactions that are sometimes difficult to manage. We investigated a chemo-activated, acyl migration-based prodrug design approach to improve the pharmacokinetic profile of 1 but failed to obtain improved oral bioavailability over dosing the parent drug in rats...
April 25, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29691760/incidence-of-symptomatic-csf-viral-escape-in-hiv-infected-patients-receiving-atazanavir-ritonavir-atv-r-containing-art-a-tertiary-care-cohort-in-western-india
#11
Atul K Patel, Ketan K Patel, Swati Gohel, Ambuj Kumar, Scott Letendre
This single-center study attempts to quantify the incidence of symptomatic CSF viral escape (CSFVE) in patients receiving atazanavir/r (ATV/r)-containing regimen. We performed a retrospective analysis of patients receiving ATV/r-containing ART who were diagnosed with symptomatic CSFVE from August 2012 to January 2017. Primary objective was to assess the incidence of symptomatic CSFVE in patients receiving ATV/r-containing ART in clinical practice. Incidence rates were calculated by dividing the number of patients who experienced CSFVE by the number of person-months at risk and summarized as per 10,000 (ten thousand) person-months at risk...
April 24, 2018: Journal of Neurovirology
https://www.readbyqxmd.com/read/29668978/atazanavir-ritonavir-with-lamivudine-as-maintenance-therapy-in-virologically-suppressed-hiv-infected-patients-96-week-outcomes-of-a-randomized-trial
#12
Massimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, Eugenia Quiros Roldan, Alessandra Latini, Gabriella d'Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Barbara Del Pin, Francesca Lombardi, Alessandro D'Avino, Emanuele Focà, Manuela Colafigli, Roberto Cauda, Simona Di Giambenedetto, Andrea De Luca
Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ritonavir + lamivudine versus continuing a standard regimen with atazanavir/ritonavir + 2NRTI in virologically suppressed patients. Methods: ATLAS-M is a 96 week open-label, randomized, non-inferiority (margin -12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA <50 copies/mL and CD4 counts >200 cells/mm3...
April 12, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29662875/positive-virological-outcomes-of-hiv-infected-patients-on-protease-inhibitor-based-second-line-regimen-in-cambodia-the-anrs-12276-2picam-study
#13
Olivier Ségéral, Eric Nerrienet, Sansothy Neth, Bruno Spire, Vohith Khol, Laurent Ferradini, Saramony Sarun, Chandara Mom, Sopheak Ngin, Charlotte Charpentier, Pagnaroat Men, Marion Mora, Vun Mean Chhi, Penhsun Ly, Vonthanak Saphonn
Background: Assessment of virological outcomes among HIV-infected patients receiving protease (PR) inhibitor-based second-line regimen are uncommon in Cambodia. The objective of this study is to assess the virological effectiveness of this regimen as well as impact of adherence boosting for patients experiencing virological failure. Methods: The 2PICAM study (Clinicaltrial: NCT01801618) is a cross-sectional study of HIV-infected adults on PR inhibitor-based second-line regimen since at least 6 months, conducted in 13 representative sites, comprising more than 90% of the target population...
2018: Frontiers in Public Health
https://www.readbyqxmd.com/read/29649076/pharmacokinetics-of-tenofovir-alafenamide-when-co-administered-with-other-hiv-antiretrovirals
#14
Rebecca Begley, Moupali Das, Lijie Zhong, John Ling, Brian P Kearney, Joseph M Custodio
BACKGROUND: Tenofovir alafenamide (TAF), a prodrug of the nucleotide analogue tenofovir (TFV), is an antiretroviral (ARV) agent approved either as a complete regimen (elvitegravir/cobicistat/emtricitabine (F)/tenofovir alafenamide (TAF), rilpivirine/F/TAF, bictegravir/F/TAF), or for use with other ARVs (F/TAF), for treatment of HIV. TAF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. Disposition of TAF may be altered by co-medications that can inhibit or induce P-gp or BCRP transporters...
April 10, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29625416/molecular-dynamics-and-ligand-docking-of-a-hinge-region-variant-of-south-african-hiv-1-subtype-c-protease
#15
Jake Zondagh, Vijayakumar Balakrishnan, Ikechukwu Achilonu, Heini W Dirr, Yasien Sayed
HIV-1 protease is an important antiretroviral drug target due to its key role in viral maturation. Computational models have been successfully used in the past to understand the dynamics of HIV-1 protease variants. We performed molecular dynamics simulations and induced fit docking on a wild-type South African HIV-1 subtype C protease and an N37T↑V hinge region variant. The simulations were initiated in a cubic cell universe and run in explicit solvent, with the wild-type and variant proteases in the fully closed conformation and under periodic boundary conditions...
March 27, 2018: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/29623097/renal-effects-of-non-tenofovir-antiretroviral-therapy-in-patients-living-with-hiv
#16
REVIEW
Milena M McLaughlin, Aimee J Guerrero, Andrew Merker
A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specifically atazanavir and indinavir, and includes reports of crystalluria, leukocyturia, nephritis, nephrolithiasis, nephropathy and urolithiasis. Several case reports describe potential nephropathy (including Fanconi syndrome) secondary to administration of abacavir, didanosine, lamivudine and stavudine...
2018: Drugs in Context
https://www.readbyqxmd.com/read/29617912/impact-of-antiretroviral-regimens-on-csf-viral-escape-in-a-prospective-multicohort-study-of-art-experienced-hiv-1-infected-adults-in-the-united-states
#17
Shibani S Mukerji, Vikas Misra, David R Lorenz, Hajime Uno, Susan Morgello, Donald Franklin, Ronald J Ellis, Scott Letendre, Dana Gabuzda
Background: Cerebrospinal fluid (CSF) viral escape occurs in 4-20% of HIV-infected adults, yet the impact of antiretroviral therapy (ART) on CSF escape is unclear. Methods: Prospective study of 1063 participants with baseline plasma viral load (VL) ≤400 copies/ml between 2005-2016. Odds ratio for ART regimens (PI with nucleoside reverse transcriptase inhibitor [PI+NRTI] versus other ART) and CSF escape was estimated using mixed-effects models. Drug resistance mutation frequencies were calculated...
April 3, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29605419/long-term-oral-atazanavir-attenuates-myocardial-infarction-induced-cardiac-fibrosis
#18
Guanghua Zhang, Xue Zhang, Defang Li, Jingwei Tian, Wanglin Jiang
Atazanavir is an antiretroviral medication used to treat and prevent HIV/AIDS, but its effects on cardiac fibrosis are unknown. The aim of this study was to determine the effects of atazanavir on myocardial infarction (MI)-induced cardiac fibrosis in rats and used a TLR 9 antagonist, hydroxychloroquine (HCQ) to elucidate the potential mechanism in vitro. The results indicated that atazanavir significantly attenuated CoCl2 -induced neonatal rat cardiac fibroblast (rCFs) proliferation in a concentration-dependent manner...
March 29, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29561293/long-term-kidney-function-proteinuria-and-associated-risks-among-hiv-infected-and-uninfected-men
#19
Frank Palella, Xiuhong Li, Samir K Gupta, Michelle M Estrella, John P Phair, Joseph B Margolick, Roger Detels, Lawrence Kingsley, Lisa P Jacobson
BACKGROUND: Factors affecting kidney function and proteinuria among HIV+ and HIV- persons need better characterization. METHODS: We evaluated estimated glomerular filtration rate (eGFR, mL/min per 1.73 m) changes, proteinuria prevalence (a urine protein-to-creatinine ratio [UPCr] of ≥0.2 at two consecutive visits) and associated factors among HIV+ and HIV- men. RESULTS: There were 917 HIV+ men receiving HAART, 159 HIV+ men not receiving HAART, and 1305 HIV- men seen from 10/2003 to 9/2014...
March 20, 2018: AIDS
https://www.readbyqxmd.com/read/29542028/cerebrospinal-fluid-drug-concentrations-and-viral-suppression-in-hiv-1-infected-patients-receiving-ritonavir-boosted-atazanavir-plus-lamivudine-dual-antiretroviral-therapy-spanish-hiv-aids-research-network-preec-ris-39
#20
Arkaitz Imaz, Jordi Niubó, Alieu Amara, Saye Khoo, Elena Ferrer, Juan M Tiraboschi, Laura Acerete, Benito Garcia, Antonia Vila, Daniel Podzamczer
This study aimed to assess cerebrospinal fluid (CSF) drug concentrations and viral suppression in HIV-1-infected patients on ritonavir-boosted atazanavir (ATV/r) plus lamivudine (3TC) dual therapy. HIV-1-infected adults with suppressed plasma HIV-1 RNA who switched to ATV/r plus 3TC were studied. Total ATV and 3TC concentrations at the end of the dosing interval (C24h ), using a validated LC-MS/MS method, and HIV-1 RNA were measured in paired CSF and plasma samples 12 weeks after switching. Ten individuals were included...
March 14, 2018: Journal of Neurovirology
keyword
keyword
114247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"